Key facts
- This page summarizes Rosty Raykov's Form 4 filing for FENNEC PHARMACEUTICALS INC. (FENC).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 02 May 2024, 16:59.
Rosty Raykov - 30 Apr 2024 Form 4 Insider Report for FENNEC PHARMACEUTICALS INC. (FENC)
- Reporting relationship
- CHIEF EXECUTIVE OFFICER, Director
- Issuer ticker
- FENC
- Reported as of
- 30 Apr 2024
- Net transaction value
- -$22,152
- SEC form
- 4
- Accepted by SEC
- 02 May 2024, 16:59:08 UTC
- Prior SEC filing
- 05 Apr 2024
- Next SEC filing
- 21 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Rostislav Raykov
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Rosty Raykov filed Form 4 for FENNEC PHARMACEUTICALS INC. (FENC) on 02 May 2024.
Change
- Previous filing in this sequence was filed on 05 Apr 2024.
- Current net transaction value: -$22,152.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
FENC
transaction
Common shares
Award
- Transaction value
- $0
- Shares
- +2,431
- Change %
- +1.3%
- Price
- $0.000000
- Shares after
- 189,902
- Date
- 30 Apr 2024
- Ownership
- Direct
- Footnotes
- F1
FENC
transaction
Common shares
Sale
- Transaction value
- $22,152
- Shares
- -2,431
- Change %
- -1.3%
- Price
- $9.11
- Shares after
- 187,471
- Date
- 01 May 2024
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 2 footnotes
Footnote F1
Represents release of restriction from shares awarded 3-31-2023
Footnote F2
Represents shares sold pursuant to a 10b5-1 plan dated December 14, 2023.